Around 5,700 people with early breast cancer are set to benefit from expanded access to a treatment combination designed to help prevent their cancer from returning, following our recommendation, ...

We welcome the publication of the government's Life Sciences Sector Plan, which sets out how NICE will ensure patients get faster, fairer access to transformative new medicines and life-changing ...

Licensed for use in the UK in March, Alyftrek will now be immediately funded by the NHS in England. This rapid timeline demonstrates NICE's commitment to getting breakthrough treatments to patients ...

A quick guide for registered managers of care homes and home care When people with care and support needs transfer into and out of hospital, good communication and integrated services are essential.

Older people All NICE products on older people. Includes any guidance, advice and quality standards. Published products on this topic (21) ...

Hybrid closed loop (HCL) systems are recommended as an option for managing blood glucose levels in type 1 diabetes for adults who have an HbA1c of 58 mmol/mol (7.5%) or more, or have disabling ...

Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapies Technology appraisal guidance TA559 Published: 23 ...

The technologies could help healthcare professionals spot hidden spinal fractures in patients undergoing routine CT scans have been conditionally recommended in draft guidance.

Guidance by programme NICE guidelines (6) Review the evidence across broad health and social care topics. Technology appraisal guidance (2) Reviews the clinical and cost-effectiveness of new ...

COVID-19 rapid guideline: managing symptoms (including at the end of life) in the community NICE guideline NG163 Published: 03 April 2020 Last updated: 13 October 2020 ...

Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Technology appraisal guidance ...

Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advanced differentiated thyroid cancer unsuitable for or refractory to radioactive iodine, in adults ...